A 5-year prospective clinical study of Neobiotech implants for partially edentulous patients.
10.4047/jkap.2017.55.3.272
- Author:
Wilmart LABRIAGA
1
;
Ju Hee HONG
;
Jin Hong PARK
;
Sang Wan SHIN
;
Jeong Yol LEE
Author Information
1. Institute for Clinical Dental Research, Korea University Medical Center, Korea University, Seoul, Republic of Korea. wddc@korea.ac.kr
- Publication Type:Original Article
- Keywords:
Dental implants;
Survival rate;
Risk factors;
Maxilla
- MeSH:
Clinical Study*;
Dental Implants;
Humans;
Korea;
Maxilla;
Methods;
Prospective Studies*;
Prostheses and Implants;
Risk Factors;
Survival Rate
- From:The Journal of Korean Academy of Prosthodontics
2017;55(3):272-278
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of the present prospective clinical study was to assess the cumulative survival rate (CSR) of Neobiotech implants restored with fixed partial prosthesis in relation to its potential risk factors. MATERIALS AND METHODS: Thirty six partially edentulous patients received Neobiotech implants and implant supported fixed partial prosthesis at Korea University Guro Hospital Dental Center from November 2009 until November 2011. The observation period was set from the implant placement and the last clinical visit until December 2015. Implant survival rate was determined using the Kaplan-Meier method. The relationship between implant survival rate and the potential risk factors were analysed using the multi Cox proportional analysis (P<.05). RESULTS: A total of 69 implants were placed in 36 patients after a mean observation period of 45.9 months. Two out of 69 implants failed before loading, yielding a 5-year cumulative survival rate of 97.1%. The maxillary implants have a lesser CSR than the mandibular implants based on log rank test analysis (maxilla=91.3%; mandible=100% P<.05). However, the multi Cox proportional analysis showed that implant location has no significant correlation with implant failure (P>.05). CONCLUSION: Neobiotech implants showed predictable results with a 5 year cumulative survival rate of 97.1%.
